First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
Aptevo Therapeutics (APVO) and Alligator Bioscience reported positive preliminary data from their Phase 1 trial of ALG.APV-527, a first-in-class bispecific antibody for solid tumors. The trial met key endpoints for safety, tolerability, and biological activity. 56% of evaluable patients (9/16) achieved stable disease, including a colon cancer patient stable for over 6 months and a breast cancer patient stable for over 11 months. Notably, no serious liver toxicity was observed, distinguishing it from other 4-1BB targeting treatments. Biomarker analysis confirmed immune activation in the tumor microenvironment, supporting the drug's mechanism of action.
Aptevo Therapeutics (APVO) e Alligator Bioscience hanno riportato dati preliminari positivi dal loro studio di Fase 1 su ALG.APV-527, un anticorpo bispecifico di prima classe per i tumori solidi. Lo studio ha raggiunto obiettivi chiave in termini di sicurezza, tollerabilità e attività biologica. Il 56% dei pazienti valutabili (9/16) ha ottenuto una malattia stabile, inclusi un paziente con cancro al colon stabile per oltre 6 mesi e un paziente con cancro al seno stabile per oltre 11 mesi. È notevole che non è stata osservata alcuna tossicità epatica grave, distinguendolo da altri trattamenti mirati a 4-1BB. L'analisi dei biomarcatori ha confermato l'attivazione immunitaria nell'ambiente tumorale, supportando il meccanismo d'azione del farmaco.
Aptevo Therapeutics (APVO) y Alligator Bioscience informaron sobre datos preliminares positivos de su ensayo de Fase 1 de ALG.APV-527, un anticuerpo bispecífico de primera clase para tumores sólidos. El ensayo cumplió con los principales criterios de seguridad, tolerabilidad y actividad biológica. El 56% de los pacientes evaluables (9/16) alcanzaron enfermedad estable, incluyendo a un paciente con cáncer de colon estable durante más de 6 meses y a un paciente con cáncer de mama estable durante más de 11 meses. Es notable que no se observó toxicidad hepática grave, lo que lo distingue de otros tratamientos dirigidos a 4-1BB. El análisis de biomarcadores confirmó la activación inmunitaria en el microambiente tumoral, apoyando el mecanismo de acción del fármaco.
Aptevo Therapeutics (APVO)와 Alligator Bioscience는 고형 종양을 위한 최초의 이중 특이성 항체인 ALG.APV-527의 1상 시험에서 긍정적인 초기 데이터를 보고했습니다. 이 시험은 안전성, 내약성 및 생물학적 활성을 위한 주요 목표를 충족했습니다. 평가 가능한 환자 중 56%(9/16)가 안정적인 질병 상태를 달성했으며, 여기에는 6개월 이상 안정적인 대장암 환자와 11개월 이상 안정적인 유방암 환자가 포함됩니다. 주목할 만한 것은 심각한 간 독성이 관찰되지 않았다는 점으로, 이는 다른 4-1BB 타겟 치료와 구별됩니다. 바이오마커 분석은 종양 미세 환경에서 면역 활성화를 확인하여 약물의 작용 기전을 지원했습니다.
Aptevo Therapeutics (APVO) et Alligator Bioscience ont rapporté des données préliminaires positives de leur essai de Phase 1 sur ALG.APV-527, un anticorps bispécifique de première classe pour les tumeurs solides. L'essai a atteint des objectifs clés en termes de sécurité, de tolérabilité et d'activité biologique. 56 % des patients évaluables (9/16) ont obtenu une maladie stable, y compris un patient atteint d'un cancer du côlon stable pendant plus de 6 mois et un patient atteint d'un cancer du sein stable pendant plus de 11 mois. Il est à noter qu'aucune toxicité hépatique grave n'a été observée, ce qui le distingue des autres traitements ciblant 4-1BB. L'analyse des biomarqueurs a confirmé l'activation immunitaire dans le microenvironnement tumoral, soutenant le mécanisme d'action du médicament.
Aptevo Therapeutics (APVO) und Alligator Bioscience berichteten von positiven vorläufigen Daten aus ihrer Phase-1-Studie zu ALG.APV-527, einem erstklassigen bispezifischen Antikörper für solide Tumoren. Die Studie erreichte wichtige Endpunkte hinsichtlich Sicherheit, Verträglichkeit und biologischer Aktivität. 56% der evaluierbaren Patienten (9/16) erreichten eine stabile Erkrankung, darunter ein Patient mit Dickdarmkrebs, der seit über 6 Monaten stabil ist, und ein Patient mit Brustkrebs, der seit über 11 Monaten stabil ist. Bemerkenswert ist, dass keine schwere Lebertoxizität beobachtet wurde, was es von anderen 4-1BB-zielgerichteten Behandlungen unterscheidet. Die Biomarker-Analyse bestätigte die Immunaktivierung im Tumormikroumfeld und unterstützte den Wirkmechanismus des Medikaments.
- 56% of evaluable patients (9/16) achieved stable disease
- No serious liver toxicity observed, unlike competing 4-1BB treatments
- Long-term stability demonstrated in two patients (6+ and 11+ months)
- Biomarker analysis confirms biological activity and immune activation
- Drug showed positive safety and tolerability across all cohorts
- Maximum tolerated dose not yet identified
- No complete or partial responses reported, only stable disease achieved
Insights
The Phase 1 trial results for ALG.APV-527 demonstrate significant promise in treating solid tumors. The 56% stable disease rate among evaluable patients is particularly noteworthy, especially given these were heavily pre-treated patients. The durability of response, with patients maintaining stable disease for 6-11 months, suggests meaningful clinical benefit.
The drug's safety profile is a important differentiator. The absence of serious liver toxicity sets it apart from other 4-1BB targeting therapies, which have historically been by hepatotoxicity. This favorable safety profile, combined with dose-proportional pharmacokinetics and evidence of immune activation in the tumor microenvironment, suggests a potentially superior therapeutic window.
The biomarker data confirming biological activity and immune activation provides mechanistic validation of the drug's design. This dual-targeting approach appears to successfully localize 4-1BB activation to the tumor site, potentially offering a solution to the historical challenges of 4-1BB targeted therapy.
For a micro-cap biotech with a market cap of just
The solid tumor market represents a massive commercial opportunity, with particular promise in breast and colon cancer based on the durability data. The lack of serious liver toxicity could be a key commercial differentiator, potentially enabling longer treatment durations and better real-world outcomes compared to existing 4-1BB targeting approaches.
Aptevo Therapeutics and Alligator Bioscience report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, more than half of evaluable patients achieved stable disease
Colon cancer patient achieved stable disease and remained on study for more than six months, breast cancer patient remained on study for more than 11 months
Biomarker analysis confirms immune activation in the tumor microenvironment
Data Presented at Society for Immunotherapy of Cancer on November 8, 2024
SEATTLE, WA and LUND, SWEDEN / ACCESSWIRE / November 11, 2024 / Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO) and Alligator Bioscience AB ("Alligator") (ATORX) today announced preliminary data from the companies' Phase 1 trial evaluating the first-in-class bispecific antibody, ALG.APV-527, as monotherapy for the treatment of multiple solid tumor types likely to express tumor antigen 5T4. These data indicate that trial endpoints of adequate exposure, safety, tolerability and biological activity were met. Outcomes were presented at a poster session on Friday November 8, 2024, at the Society for Immunotherapy of Cancer Conference in Houston, Texas.
"The interim results from Phase 1 trials of ALG.APV-527 are showing encouraging outcomes, particularly in terms of safety and disease stability in the trial patients who were refractory to multiple previous therapies. Among evaluable patients,
Clinical Highlights
Safety and Tolerability
ALG.APV-527 demonstrated positive safety and tolerability across all cohorts
No serious liver toxicity, a common side effect of other 4-1BB targeting treatments that can cause patients to discontinue dosing, was observed
A maximum tolerated dose has not been identified, highlighting the tolerability of the drug at high dose levels
Clinical Activity/Efficacy
Nine of 16 efficacy evaluable patients (
56% ) achieved stable disease (SD)One colon cancer patient achieved SD for more than six months
The longest SD duration was in a breast cancer patient who entered the study with progressive disease, achieved stable disease and remained on study for >11 months. This patient successfully transitioned to a higher dose level twice
Evidence of biological activity of ALG.APV-527
ALG.APV-527 could be measured in all patients. Serum concentrations of ALG.APV-527 were proportional to the administered dose
Analysis of biomarkers in the serum of treated patients including soluble 4-1BB (surface protein found on certain immune cells) confirm biological activity of ALG.APV-527
Analysis of biomarkers in biopsies (including the 5T4 target cells and CD8 T cancer killer cells are consistent with immune activation in the tumor microenvironment). This observation consistent with ALG.APV-527 expected MOA.
About the Trial
The ALG.APV-527 Phase 1 trial is a multi-center, multi-cohort, open-label dose-escalation trial that includes administration of ALG.APV-527 in up to six escalating dose levels in a 3+3 design*. The trial is enrolling adult patients with multiple solid tumor types/histologies likely to express the 5T4 antigen. ALG.APV-527 will be given intravenously once every two weeks. The trial is assessing the safety and tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of ALG.APV-527.
*The 3+3 design proceeds in cohorts of three patients treated at increasing dose levels. Dose escalation stops when at least two out of three or six patients experience dose limiting toxicities (DLTs) at that dose level.
About ALG.APV-527
ALG.APV-527 is a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4. This has the potential to be clinically important because 4-1BB can stimulate the immune cells (antitumor-specific T cells and NK cells) involved in tumor control, making 4-1BB a particularly compelling target for cancer immunotherapy. 5T4 is an oncofetal tumor associated antigen overexpressed on numerous solid tumors including non-small-cell lung carcinoma (NSCLC), breast, head and neck, cervical, renal, gastric, and colorectal cancer.
Preclinical studies, highlighting the differentiated design of the molecule that minimizes systemic immune activation, allowing for highly efficacious tumor-specific responses as demonstrated by potent activity in preclinical models, has been published in the peer-reviewed publication, Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR).
About Aptevo Therapeutics
Aptevo Therapeutics Inc. (Nasdaq: APVO) is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The company has two clinical candidates. Mipletamig is currently being evaluated in RAINIER, a Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation ("orphan status") for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates were created from two proprietary platforms, ADAPTIRâ and ADAPTIR-FLEXâ. The Aptevo mission is to improve treatment outcomes and transform the lives of cancer patients. For more information, please visit www.aptevotherapeutics.com.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.
Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden. For more information, please visit alligatorbioscience.com.
For additional information, please contact:
Aptevo Therapeutics
Miriam Weber Miller
Aptevo Therapeutics
IR@apvo.com or millerm@apvo.com
+1 (206) 859 6629
Alligator Bioscience
Corporate
Søren Bregenholt, CEO
soren.bregenholt@alligatorbioscience.com
+46 46-540 82 00
Media
Sam Cage
Cohesion Bureau
sam.cage@cohesionbureau.com
+45 24 37 63 42
Investors
Frank Hoerning Andersen
Cohesion Bureau
frank.hoerning@cohesionbureau.com
+45 25 66 86 02
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations about the activity, efficacy, safety, tolerability and durability of its therapeutic candidates and potential use of any such candidates, including in combination with other drugs, as therapeutics for treatment of disease, its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platforms, statements related to the progress of Aptevo's clinical programs, including statements related to anticipated clinical and regulatory milestones, whether further study of mipletamig in a Phase 1b dose optimization trial focusing on multiple doses of mipletamig in combination with venetoclax + azacitidine on a targeted patient population will continue to show clinical benefit, whether Aptevo's final trial results will vary from its earlier assessment, whether further study of ALG.APV-527 across multiple tumor types will continue to show clinical benefit, whether higher dose ranges for ALG.APV-527 will result in increased signs of clinical activity, whether biomarker analyses will continue to confirm biological activity of ALG.APV-527, the possibility and timing of future preliminary or interim data readouts for ALG.APV-527, whether Aptevo's final trial results will vary from its preliminary or interim assessments, statements related to the progress of and enthusiasm for Aptevo's clinical programs, statements related to Aptevo's ability to generate stockholder value, whether Aptevo will continue to have momentum in its business in the future, and any other statements containing the words "may," "continue to," "believes," "knows," "expects," "optimism," "potential," "designed," "promising," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.
There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems, adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; and changes in regulatory, social, macroeconomic and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the results of preliminary or interim data and preclinical studies being predictive of the results of later-stage clinical trials, initiation, enrollment and maintenance of patients, and the completion of clinical trials, the availability and timing of data from ongoing clinical trials, the trial design includes combination therapies that may make it difficult to accurately ascertain the benefits of mipletamig, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners or raise funds on acceptable terms or at all and other matters that could affect the availability or commercial potential of Aptevo's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the coronavirus (referred to as COVID-19), geopolitical risks, including the current war between Russia and Ukraine, war between Israel and Hamas, and macroeconomic conditions such as economic uncertainty, rising inflation and interest rates, continued market volatility and decreased consumer confidence and uncertainty in the impact of the results of the United States presidential election and congressional election. These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances.
SOURCE: Aptevo Therapeutics
View the original press release on accesswire.com
FAQ
What were the main results of Aptevo's (APVO) Phase 1 trial for ALG.APV-527?
How many patients achieved stable disease in APVO's ALG.APV-527 Phase 1 trial?
What distinguishes ALG.APV-527 from other 4-1BB targeting treatments?
What was the longest duration of stable disease in APVO's Phase 1 trial?
